Pediatric acute myeloid leukemia as classified using 2008 WHO criteria: a single-center experience.

The classification of acute myeloid leukemia (AML) has evolved to the most recent World Health Organization (WHO) schema, which integrates genetic, morphologic, and prognostic data into a single system. However, this system was devised using adult data and how this system applies to a pediatric cohort is unknown. Performing a retrospective chart review, we examined our single-center experience with AML in 115 children and classified their leukemia using the WHO 2008 schema. We examined patient samples for mutations of FLT3, NPM1, and CEBPA. Overall survival was calculated within categories. In our pediatric population, most cases of AML had recurrent genetic abnormalities of favorable prognosis. More than 10% of patients in our series were categorized as AML, with myelodysplasia-related changes, an entity not well-described in pediatric patients. In addition, a large proportion of patients were categorized with secondary, therapy-related AML. To our knowledge, this is the first application of the WHO 2008 classification to a pediatric cohort. In comparison to adult studies, AML in the pediatric population shows a distinct distribution within the WHO 2008 classification.

[1]  G. Armstrong,et al.  Long-term risk for subsequent leukemia after treatment for childhood cancer: a report from the Childhood Cancer Survivor Study. , 2011, Blood.

[2]  E. van den Berg,et al.  Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Hills,et al.  Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Y. Hayashi,et al.  Prognostic significance of the BAALC isoform pattern and CEBPA mutations in pediatric acute myeloid leukemia with normal karyotype: a study by the Japanese Childhood AML Cooperative Study Group , 2010, International journal of hematology.

[5]  Susan C. Weber,et al.  STRIDE - An Integrated Standards-Based Translational Research Informatics Platform , 2009, AMIA.

[6]  D. Arber,et al.  A comparison of two methods for screening CEBPA mutations in patients with acute myeloid leukemia. , 2009, The Journal of molecular diagnostics : JMD.

[7]  R. Larson.  Therapy-related myeloid neoplasms , 2009, Haematologica.

[8]  S. Raimondi,et al.  Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. , 2009, Blood.

[9]  J. Merker,et al.  Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. , 2008, Blood.

[10]  S. Pileri,et al.  NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia , 2008, Haematologica.

[11]  S. Adachi,et al.  Acute Myeloid Leukemia with Multilineage Dysplasia in Children , 2007, International journal of hematology.

[12]  R. Arceci,et al.  The incidence and clinical significance of nucleophosmin mutations in childhood AML. , 2007, Blood.

[13]  S. Raimondi,et al.  Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. , 2007, Blood.

[14]  C. Bloomfield,et al.  A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ‘poor prognosis’ myeloid malignancies , 2006, Leukemia.

[15]  Gerhard Ehninger,et al.  Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). , 2006, Blood.

[16]  Stefan Fröhling,et al.  Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. , 2005, Blood.

[17]  D. Webb.  Optimizing therapy for myeloid disorders of Down syndrome , 2005, British journal of haematology.

[18]  C. Preudhomme,et al.  CEBPA point mutations in hematological malignancies , 2005, Leukemia.

[19]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.

[20]  D. Liang,et al.  CEBPα mutations in childhood acute myeloid leukemia , 2004, Leukemia.

[21]  J. Radich,et al.  FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. , 2003, Blood.

[22]  M. Slovak,et al.  Prognostic Impact of Acute Myeloid Leukemia Classification , 2003 .

[23]  M. Slovak,et al.  Prognostic impact of acute myeloid leukemia classification. Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. , 2003, American journal of clinical pathology.

[24]  M. Tomonaga,et al.  Cytogenetic heterogeneity of acute myeloid leukaemia (AML) with trilineage dysplasia: Japan Adult Leukaemia Study Group‐AML 92 study , 2003, British journal of haematology.

[25]  T. Rebbeck,et al.  Differential bone marrow aspirate DNA yields from commercial extraction kits , 2002, Leukemia.

[26]  J. Bennett,et al.  Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival. , 1992, Leukemia.

[27]  F. Naeim.  21 – Acute Myeloid Leukemia, Not Otherwise Specified , 2013 .

[28]  R. Pieters,et al.  Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML , 2009, Leukemia.

[29]  J. Bennett,et al.  B-Lymphoblastic Leukemia/Lymphoma , 2014 .